Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2009;53:387-392
Published online before print November 24, 2008, doi: 10.1161/HYPERTENSIONAHA.108.124776
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
53/2_Part_2/387    most recent
HYPERTENSIONAHA.108.124776v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by da Costa Goncalves, A. C.
Right arrow Articles by Gross, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by da Costa Goncalves, A. C.
Right arrow Articles by Gross, V.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetic Nerve Problems
*High Blood Pressure
Hazardous Substances DB
*ENALAPRIL MALEATE
Related Collections
Right arrow Obesity
Right arrow Animal models of human disease
Right arrow Type 2 diabetes

(Hypertension. 2009;53:387.)
© 2009 American Heart Association, Inc.


Original Articles Part 2

Diabetic Hypertensive Leptin Receptor–Deficient db/db Mice Develop Cardioregulatory Autonomic Dysfunction

Andrey C. da Costa Goncalves; Jens Tank; André Diedrich; Aline Hilzendeger; Ralph Plehm; Michael Bader; Friedrich C. Luft; Jens Jordan; Volkmar Gross

From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., A.H., R.P., M.B., F.C.L., V.G.), Berlin, Germany; Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; Division of Clinical Pharmacology (A.D.), Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; Department of Biophysics (A.H.), Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil; and the Medical Faculty of the Charité (F.C.L.), Franz Volhard Clinic, HELIOS Klinikum, Berlin, Germany

Correspondence to Volkmar Gross, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10,13125 Berlin, Germany. E-mail vgross{at}mdc-berlin.de

Leptin receptor–deficient db/db mice develop human type 2 diabetes mellitus, hypertension, and obesity with disrupted circadian blood pressure (BP) rhythm. Whether leptin is the sole mechanism mediating autonomic imbalance and hypertension is unclear. To explore this notion further, we measured BP by radiotelemetry combined with fast Fourier transformation and assessed autonomic function pharmacologically before and after renin-angiotensin system blockade with enalapril. The resting period BP (117±3 versus 108±1.0 mm Hg) and heart rate (HR; 488±12 versus 436±8 bpm) were higher in db/db mice compared with db/+ mice. BP and HR amplitudes were lower in db/db mice compared with db/+ mice. BP response to trimetaphan (–43±5 versus –27±3 mm Hg) and HR response to metoprolol (–59±12 versus –5±4 bpm) were greater in db/db mice than in db/+ mice. The HR response to atropine was blunted in db/db mice (59±17 versus 144±24 bpm), as were baroreflex sensitivity and HR variability. Enalapril improved autonomic regulation in db/db mice. Stimulation of central {alpha}-2 adrenoreceptors enhanced both parasympathetic HR control and baroreflex sensitivity in db/db mice. We suggest that functional, rather than structural, {alpha}-2 adrenoceptor changes and the renin-angiotensin system are involved in the increased sympathetic and decreased parasympathetic tones in db/db mice. Our data suggest that db/db mice exhibit features found in humans with type 2 diabetic autonomic neuropathy and could serve as a model for this complication.


Key Words: type 2 diabetes mellitus • obesity • hypertension • ACE inhibition • {alpha}-2 adrenoceptors • autonomic dysfunction




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
R. D. Rudic and D. J. Fulton
Pressed for time: the circadian clock and hypertension
J Appl Physiol, October 1, 2009; 107(4): 1328 - 1338.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. Gutkowska, T. L. Broderick, D. Bogdan, D. Wang, J.-M. Lavoie, and M. Jankowski
Downregulation of oxytocin and natriuretic peptides in diabetes: possible implications in cardiomyopathy
J. Physiol., October 1, 2009; 587(19): 4725 - 4736.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. Thorin and N. Thorin-Trescases
Vascular endothelial ageing, heartbeat after heartbeat
Cardiovasc Res, October 1, 2009; 84(1): 24 - 32.
[Abstract] [Full Text] [PDF]


Home page
DMMHome page
H. Bugger and E. D. Abel
Rodent models of diabetic cardiomyopathy
Dis. Model. Mech., September 1, 2009; 2(9-10): 454 - 466.
[Abstract] [Full Text] [PDF]